Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

The one problem Lilly has faced is meeting the soaring demand for these products. In fact, they are so popular that the U.S.

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

We recently compiled a list of the 10 stocks that will make you rich in 5-10 years. In this article, we are going to take a ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.